← Organon & overview

Organon & vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Organon & Co (OGN)

Q2 2026
▲2▼2

Organon's $11.75B Sun Pharma takeover, new product deals, and weak Q1 revenue

  • Sun Pharma's $11.75B takeover of Organon Sun Pharmaceutical is acquiring Organon for $14.00 per share in cash, a deal valued at $11.75 billion. This provides a premium to shareholders and is the main reason OGN is moving. The deal is part of a broader M&A surge in biopharma.

    This is the biggest driver of OGN's price, as it sets a floor and provides a clear exit for shareholders.

  • Investigation into Organon board over merger Brodsky & Smith is investigating Organon's board for potential fiduciary duty breaches in the merger agreement. This could delay the deal or reduce the consideration shareholders receive, creating uncertainty and potential downside for OGN.

    This is a new risk that could affect the deal's completion or terms, directly impacting OGN's price.

  • Organon licenses MIUDELLA, a hormone-free IUD Organon secured exclusive global rights to MIUDELLA, the first new hormone-free copper IUD in over 40 years. This expands Organon's contraception portfolio and addresses unmet demand for non-hormonal options, supporting future revenue growth.

    This is a new product addition that strengthens Organon's core business and long-term growth prospects.

  • Organon Q1 revenue fell 3.5%, missing estimates Organon reported Q1 revenue of $1.46 billion, down 3.5% and below expectations. This weak operational performance contrasts with the takeover premium and highlights challenges in the core business, which could weigh on the stock if the deal falls through.

    This is new financial data showing underlying weakness, a counterweight to the positive deal news.

June 2026
▲2▼2

Organon's $11.75B Sun Pharma takeover, new product deals, and weak Q1 revenue

  • Sun Pharma's $11.75B takeover of Organon Sun Pharmaceutical is acquiring Organon for $14.00 per share in cash, a deal valued at $11.75 billion. This provides a premium to shareholders and is the main reason OGN is moving. The deal is part of a broader M&A surge in biopharma.

    This is the biggest driver of OGN's price, as it sets a floor and provides a clear exit for shareholders.

  • Investigation into Organon board over merger Brodsky & Smith is investigating Organon's board for potential fiduciary duty breaches in the merger agreement. This could delay the deal or reduce the consideration shareholders receive, creating uncertainty and potential downside for OGN.

    This is a new risk that could affect the deal's completion or terms, directly impacting OGN's price.

  • Organon licenses MIUDELLA, a hormone-free IUD Organon secured exclusive global rights to MIUDELLA, the first new hormone-free copper IUD in over 40 years. This expands Organon's contraception portfolio and addresses unmet demand for non-hormonal options, supporting future revenue growth.

    This is a new product addition that strengthens Organon's core business and long-term growth prospects.

  • Organon Q1 revenue fell 3.5%, missing estimates Organon reported Q1 revenue of $1.46 billion, down 3.5% and below expectations. This weak operational performance contrasts with the takeover premium and highlights challenges in the core business, which could weigh on the stock if the deal falls through.

    This is new financial data showing underlying weakness, a counterweight to the positive deal news.

Latest
▲2▼2

Organon's $11.75B Sun Pharma takeover, new product deals, and weak Q1 revenue

  • Sun Pharma's $11.75B takeover of Organon Sun Pharmaceutical is acquiring Organon for $14.00 per share in cash, a deal valued at $11.75 billion. This provides a premium to shareholders and is the main reason OGN is moving. The deal is part of a broader M&A surge in biopharma.

    This is the biggest driver of OGN's price, as it sets a floor and provides a clear exit for shareholders.

  • Investigation into Organon board over merger Brodsky & Smith is investigating Organon's board for potential fiduciary duty breaches in the merger agreement. This could delay the deal or reduce the consideration shareholders receive, creating uncertainty and potential downside for OGN.

    This is a new risk that could affect the deal's completion or terms, directly impacting OGN's price.

  • Organon licenses MIUDELLA, a hormone-free IUD Organon secured exclusive global rights to MIUDELLA, the first new hormone-free copper IUD in over 40 years. This expands Organon's contraception portfolio and addresses unmet demand for non-hormonal options, supporting future revenue growth.

    This is a new product addition that strengthens Organon's core business and long-term growth prospects.

  • Organon Q1 revenue fell 3.5%, missing estimates Organon reported Q1 revenue of $1.46 billion, down 3.5% and below expectations. This weak operational performance contrasts with the takeover premium and highlights challenges in the core business, which could weigh on the stock if the deal falls through.

    This is new financial data showing underlying weakness, a counterweight to the positive deal news.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

September 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

Latest
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.